Powered by: Motilal Oswal
25/07/2023 5:39:03 PM | Source: PR Agency
IPO Research Report -Yatharth Hospital and Trauma Care Services Limited
News By Tags | #442

Yatharth Hospital and Trauma Care Services Ltd.

Company Background

Yatharth Hospital and Trauma Care Services Limited (YHTCL) was incorporated on February 28, 2008. It is a multi-care hospital chain. It rank among the top 10 largestprivate hospitals in the National Capital Region of Delhi. Yatharth Hospital presently operates three super specialty hospitals situated in Delhi NCR, i.e., at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. It offer healthcare services across numerous specialties and super specialties. A team of 609 doctors is engaged with the company.

Issue Details

Fresh Issue of Equity shares aggregating upto ?490 Cr and Offer for sale of 6,551,690 Equity Shares.

Issue Objectives

1. Repayment/ prepayment, in full or part, of certain borrowings availed by the Company.

2. Repayment/ prepayment, in full or part, of certain borrowings availed by the Subsidiaries, namely, AKS Medical & Research Centre Private Limited and Ramraja Multispeciality Hospital & Trauma Centre Private Limited.

3. Funding capital expenditure expenses of the Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital.

4. Funding capital expenditure expenses of the Subsidiaries, AKS and Ramraja, for respective hospitals operated by them.

5. Funding inorganic growth initiatives through acquisitions and other strategic initiatives.

6. General corporate purposes.

IPO share allotment pattern

Outlook and Valuations

YHTCL is among the leading super specialty hospital in Delhi-NCR region with diverse specialty and payer mix. The company has advanced and high end medical equipment and technology. Further, we believe active collaborations with leading institutions and experts in different medical areas to improve their diagnostic and treatment capabilities and expansion in other geographical areas through inorganic growth to drive growth. At the upper price band of ?300/-, stock is priced at 29.73 of its FY23 EPS of 10.09. We recommend subscribing to the issue from a long term perspective.

 

To Read Complete Report & Disclaimer Click Here

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here